T(6;11) Renal cell carcinoma (RCC): Expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases

American Journal of Surgical Pathology

Volumn 38, Issue 5, 2014, Pages 604-614

  Smith, Nathaniel E ^a   Illei, Peter B ^a   Allaf, Mohamed ^b   Gonzalez, Nilda ^a   Morris, Kerry ^a   Hicks, Jessica ^a   Demarzo, Angelo ^a,c   Reuter, Victor E ^d   Amin, Mahul B ^e   Epstein, Jonathan I ^a   Netto, George J ^a   Argani, Pedram ^a,c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b Departments of Urology   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

biomarkers; renal cell carcinoma; TFEB

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 11; CHROMOSOME 6; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; TISSUE MICROARRAY; YOUNG ADULT;

ADULT; AGED; CARCINOMA, RENAL CELL; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899491174     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000203     Document Type: Article

References (59)

1. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renalneoplasm characterized by epithelioid morphology, basementmembrane production, focal HMB45 immunoreactivity, andt(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158:2089-2096. (Pubitemid 32545194)
2. Srigley JR, Delahunt B, Eble JN, et al. The International Society ofUrological Pathology (ISUP) Vancouver Classification of RenalNeoplasia. Am J Surg Pathol. 2013;37:1469-1489.
3. Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an Alpha-TFEBfusion in renal tumors harboring the t(6;11)(p21;q13) chromosometranslocation. Proc Natl Acad Sci USA. 2003;100:6051-6056. (Pubitemid 36576929)
4. Kuiper RP, Schepens M, Thijssen J, et al. Upregulation of thetranscription factor TFEB in t(6;11)(p21;q13)-positive renal cellcarcinomas due to promoter substitution. Hum Mol Genet. 2003;12:1661-1669. (Pubitemid 36896659)
5. Argani P, Lui MY, Couturier J, et al. A novel CLTC-TFE3 genefusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).Oncogene. 2003;22:5374-5378. (Pubitemid 37056101)
6. Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusionpatterns and heterogeneous clinicopathologic features of renalcell carcinoma with t(6;11) translocation. Am J Surg Pathol.2012;36:35-42.
7. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas witht(6;11)(p21;q12): a clinicopathologic study emphasizing unusualmorphology, novel Alpha-TFEB gene fusion point, immunobiomarkers,and ultrastructural features, as well as detection of the genefusion by fluorescence in situ hybridization. Am J Surg Pathol.2012;36:1327-1338.
8. Hora M, Hes O, Urge T, et al. A distinctive translocation carcinomaof the kidney ["rosette-like forming," t(6;11), HMB45-positive renaltumor]. Int Urol Nephrol. 2009;41:553-557.
9. Pecciarini L, Cangi MG, Lo Cunsolo C, et al. Characterization oft(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. GenesChromosomes Cancer. 2007;46:419-426. (Pubitemid 46449244)
10. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas withthe t(6;11)(p21;q12): clinicopathologic features and demonstrationof the specific Alpha-TFEB gene fusion by immunohistochemistry,RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230-240. (Pubitemid 40170642)
11. Martignoni G, Gobbo S, Camparo P, et al. Differential expressionof cathepsin K in neoplasms harboring TFE3 gene fusions. ModPathol. 2011;24:1313-1319.
12. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivitydistinguishes MiTF/TFE family renal translocation carcinomasfrom other renal carcinomas. Mod Pathol. 2009;22:1016-1022.
13. Argani P, Hicks J, DeMarzo AM, et al. Xp11 translocation renal cellcarcinoma (RCC): extended immunohistochemical profile emphasizingnovel RCC markers. Am J Surg Pathol. 2010;34:1295-1303.
14. Ishihara A, Yamashita Y, Takamori H, et al. Renal carcinoma with(6;11)(p21;q12) translocation: report of an adult case. Pathol Int.2011;61:539-545.
15. Zhan HQ, Wang CF, Zhu XZ, et al. Renal cell carcinoma witht(6;11) translocation: a patient case with a novel Alpha-TFEBfusion point. J Clin Oncol. 2010;28:e709-e713.
16. Argani P, Yonescu R, Morsberger L, et al. Molecular confirmationof t(6;11)(p21;q12) renal cell carcinoma in archival paraffinembeddedmaterial using a break-apart TFEB FISH assay expandsits clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516-1526.
17. Petersson F, Michal M, Vanecek T, et al. Bilateral renal tumors;conventional clear cell carcinoma and contralateral t(6;11)/t(X;17)-like tumor histomorphologic, immunohistochemical, ultrastructuraland molecular genetic studies including the report of a novelmutation in the VHL gene. Ann Diagn Pathol. 2011;15:362-369.
18. Suarez-Vilela D, Izquierdo-Garcia F, Mendez-Alvarez JR, et al.Renal translocation carcinoma with expression of TFEB: presentationof a case with distinctive histological and immunohistochemicalfeatures. Int J Surg Pathol. 2011;19:506-509.
19. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adultrenal tumors. Hum Pathol. 2001;32:282-287.
20. Mazal PR, Stichenwirth M, Koller A, et al. Expression ofaquaporins and PAX-2 compared to CD10 and cytokeratin 7 inrenal neoplasms: a tissue microarray study. Mod Pathol.2005;18:535-540. (Pubitemid 40478117)
21. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX8 as auseful marker in distinguishing ovarian carcinomas from mammarycarcinomas. Am J Surg Pathol. 2008;32:1566-1571.
22. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis ofprimary renal tumors: immunohistochemical comparison with renalcell carcinoma marker antigen and kidney-specific cadherin. Am JClin Pathol. 2009;131:393-404.
23. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX8in nephrogenic adenoma and clear cell adenocarcinoma of the lowerurinary tract: evidence of related histogenesis Am J Surg Pathol.2008;32:1380-1387.
24. Gupta R, Balzer B, Picken M, et al. Diagnostic implications oftranscription factor Pax 2 protein and transmembrane enzymecomplex carbonic anhydrase IX immunoreactivity in adult renalepithelial neoplasms. Am J Surg Pathol. 2009;33:241-247.
25. Kelsh RN. Sorting out Sox10 functions in neural crest development.Bioessays. 2006;28:788-798. (Pubitemid 44433741)
26. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31,BerEP4, RCC marker and CD10 in the classification of renal cellcarcinoma and renal oncocytoma: an immunohistochemical analysisof 328 cases. Histopathology. 2004;45:452-459. (Pubitemid 39524319)
27. Langner C, Ratschek M, Rehak P, et al. Expression of MUC1(EMA) and E-cadherin in renal cell carcinoma: a systematicimmunohistochemical analysis of 188 cases. Mod Pathol. 2004;17:180-188. (Pubitemid 41656514)
28. Argani P, Ladanyi M. Translocation carcinomas of the kidney. ClinLab Med. 2005;25:363-378. (Pubitemid 40545824)
29. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemicalexpression of hypoxia inducible factor-1alpha and its downstreammolecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258-1263. (Pubitemid 46436019)
30. Trzpis M, McLaughlin PM, de Leij LM, et al. Epithelial celladhesion molecule: more than a carcinoma marker and adhesionmolecule. Am J Pathol. 2007;171:386-395. (Pubitemid 47344671)
31. Went P, Dirnhofer S, Salvisberg T, et al. Expression of epithelial celladhesion molecule (EpCam) in renal epithelial tumors. Am J SurgPathol. 2005;29:83-88. (Pubitemid 40023954)
32. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution ofcytokeratins and vimentin in adult renal neoplasms and normal renaltissue: potential utility of a cytokeratin antibody panel in the differentialdiagnosis of renal tumors. Am J Surg Pathol. 2005;29:747-754. (Pubitemid 40734424)
33. Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renalcarcinomas: morphologic, immunohistochemical, ultrastructural, andmolecular analysis of an entity associated with the t(X;1)(p11.2;q21).Am J Surg Pathol. 2002;26:1553-1566.
34. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasmswith the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: adistinctive tumor entity previously included among renal cellcarcinomas of children and adolescents. Am J Pathol. 2001;159:179-192. (Pubitemid 33704203)
35. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl-CoA racemase in papillary renal cell carcinoma. Am JSurg Pathol. 2004;28:69-76. (Pubitemid 38031623)
36. Wang HY, Mills SE. KIT and RCC are useful in distinguishingchromophobe renal cell carcinoma from the granular variantof clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29:640-646. (Pubitemid 40577874)
37. Petit A, Castillo M, Santos M, et al. KIT expression inchromophobe renal cell carcinoma: comparative immunohistochemicalanalysis of KIT expression in different renal cell neoplasms. AmJ Surg Pathol. 2004;28:676-678. (Pubitemid 38579572)
38. Thedieck C, Kuczyk M, Klingel K, et al. Expression of Kspcadherinduring kidney development and in renal cell carcinoma. BrJ Cancer. 2005;92:2010-2017. (Pubitemid 40897423)
39. Adley BP, Gupta A, Lin F, et al. Expression of kidney-specificcadherin in chromophobe renal cell carcinoma and renal oncocytoma.Am J Clin Pathol. 2006;126:79-85. (Pubitemid 44025074)
40. Kuehn A, Paner GP, Skinnider BF, et al. Expression analysis ofkidney-specific cadherin in a wide spectrum of traditional and newlyrecognized renal epithelial neoplasms: diagnostic and histogeneticimplications. Am J Surg Pathol. 2007;31:1528-1533. (Pubitemid 47482465)
41. Horstmann M, Geiger LM, Vogel U, et al. Kidney-specific cadherincorrelates with the ontogenetic origin of renal cell carcinomasubtypes: an indicator of a malignant potential World J Urol.2012;30:525-531.
42. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevanceof the mTOR pathway in renal cell carcinoma: implications formolecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267. (Pubitemid 46801555)
43. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromaltumors: an immunohistochemical study including a comparison ofcalretinin and inhibin. Mod Pathol. 2003;16:584-590. (Pubitemid 36718440)
44. Antic T, Meyer P, Pins M, et al. TFEB immunopositivity in renalangiomyolipomas [Abstract #608]. Mod Pathol. 2007;20(S2):135A.
45. Sironi M, Spinelli M. Oncocytic angiomyolipoma of the kidney: acase report. Int J Surg Pathol. 2003;11:229-234. (Pubitemid 36919970)
46. El-Hashemite N, Zhang H, Henske EP, et al. Mutation in TSC2 andactivation of mammalian target of rapamycin signalling pathway inrenal angiomyolipoma. Lancet. 2003;361:1348-1349. (Pubitemid 36514870)
47. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferonalfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
48. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSCmTORpathway in human disease. Nat Genet. 2005;37:19-24.
49. Wienecke R, Fackler I, Linsenmaier U, et al. Antitumoral activity ofrapamycin in renal angiomyolipoma associated with tuberoussclerosis complex. Am J Kidney Dis. 2006;48:e27-e29. (Pubitemid 44262422)
50. Peces R, Peces C, Cuesta-Lopez E, et al. Low-dose rapamycinreduces kidney volume angiomyolipomas and prevents the loss ofrenal function in a patient with tuberous sclerosis complex. NephrolDial Transplant. 2010;25:3787-3791.
51. Curran MP. Everolimus: in patients with subependymal giant cellastrocytoma associated with tuberous sclerosis complex. PaediatrDrugs. 2012;14:51-60.
52. Geller JI, Argani P, Adeniran A, et al. Translocation renal cellcarcinoma: lack of negative impact due to lymph node spread.Cancer. 2008;112:1607-1616. (Pubitemid 351441175)
53. Martignoni G, Tardanico R, Pea M, et al. t(6;11) renal cell tumor: aclinicopathological study of two cases in adults [abstract 715]. ModPathol. 2005;18:155A.
54. Petersson F, Vanecek T, Michal M, et al. A distinctive translocationcarcinoma of the kidney: "rosette forming," t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. Hum Pathol.2012;43:726-736.
55. Argani P, Laé M, Ballard ET, et al. Translocation carcinomas ofthe kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529-1534. (Pubitemid 46638774)
56. Camparo P, Vasiliu V, Molinie V, et al. Renal translocationcarcinomas: clinicopathologic, immunohistochemical, and geneexpression profiling analysis of 31 cases with a review of theliterature. Am J Surg Pathol. 2008;32:656-670. (Pubitemid 351600831)
57. Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-apartFISH assay on paraffin-embedded tissues as an adjunct to diagnosisof Xp11 translocation renal cell carcinoma and alveolar soft partsarcoma. Am J Surg Pathol. 2010;34:757-766.
58. Rao Q, Zhang X-M, Tu P, et al. Renal cell carcinomas witht(6;11)(p21;q12) presenting with tubulocystic-like features. Int J ClinExp Pathol. 2013;6:1452-1457.
59. Matsuura K, Inoue T, Kai T, et al. Molecular analysis of a case ofrenal cell carcinoma with t(6;11)(p21;q12) reveals a link to alysosome-like structure. Histopathology. (In press).